anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Alzheimer's disease (AD) is a progressive neurodegenerative disorder that is characterized by several pathological hallmarks, including the deposition of amyloid-β (Aβ) plaques, neurofibrillary tangles, blood-brain barrier (BBB) dysfunction, increased oxidative stress, and neuroinflammation. Current treatment options include monoclonal antibody drugs, acetylcholinesterase, and n-methyl-d-aspartate (NMDA) antagonists. Although those treatments provide some improvements in patients' quality of life, they fail to prevent or cure AD. Current research aims to identify novel targets and tools for AD prevention and modification. In this context, several studies showed the beneficial effect of the Mediterranean diet in the prevention and treatment of AD. One integral component of the Mediterranean diet is olive oil and extra-virgin olive oil (EVOO), which is high in phenolic compounds. EVOO and other olive-related phenolic compounds have been shown to reduce the risk of developing mild cognitive impairment (MCI) and AD. In this review, we discuss the mechanisms by which EVOO and phenolic compounds exert neuroprotective effects, including modulation of AD pathologies and promotion of cognitive health. Findings indicate that EVOO and its phenolic constituents influence key pathological processes of AD, such as Aβ aggregation, tau phosphorylation, and neuroinflammation, while also enhancing BBB integrity and reducing oxidative stress. The human studies cited reveal a consistent trend where the consumption of olive oil is associated with cognitive benefits and a decreased risk of AD and related dementias. In conclusion, EVOO and its phenolic compounds hold promising potential for the prevention and treatment of AD, representing a significant shift towards more effective strategies against this complex neurodegenerative disorder.
HAPTENS, HAPTEN CONJUGATES, COMPOSITIONS THEREOF AND METHOD FOR THEIR PREPARATION AND USE 5OF THE DISCLOSURE A method for performing a multiplexed diagnostic assay, such as for two or more different targets in a sample, is described. One embodiment comprised contacting the sample with two or more specific binding moieties that bind specifically to two or 10 more different targets. The two or more specific binding moieties are conjugated to different haptens, and at least one of the haptens is an oxazole, a pyrazole, a thiazole, a nitroaiyl compound other than dinitrophenyl, a benzofurazan, a triterpene, a urea, a thiourea, a rotenoid, a coumarin, a cyclolignan, a heterobiaryl, an azo aryl, or a benzodiazepine. The sample is contacted with two or more different anti-hapten 15 antibodies that can be detected separately. The two or more different anti-hapten antibodies may be conjugated to different detectable labels. 10121855_1 (GH Matters) P80514 AU.3 29/03118
PURPOSE: A composition containing Aruncus dioicus var. kamtschaticus HARA extract is provided to ensure antioxidation, anti-inflammation, whitening, and anti-wrinkling without side effect or toxicity. CONSTITUTION: A cosmetic composition with antioxidation, anti-inflammation, whitening, and anti-wrinkling effects contains Aruncus dioicus var. kamtschaticus HARA extract as an active ingredient. The extract is a crude extract, polar solvent soluble extract, or non-polar soluble extract. The crude extract is prepared using water including purified water, spirit, C1-4 low alcohol, acetone, chloroform, methylene chloride, hexane, or a mixture solvent thereof. The non-polar soluble extract is prepared using ethyl acetate, chloroform, hexane, and dichloromethane. The cosmetic composition is manufactured in the form of a lotion, skin, nutrition cream, massage cream, essence, and pack.
The invention discloses a hollow rectal suppository containing medicines, belongs to the technical field of medical and health, and can solve the problem that the traditional suppository is easy to be discharged from a body. The whole medicated hollow rectal suppository is cylinder-like and consists of an outer part suppository shell and an inner part spring, and the inner part is hollow. The hollow structure can provide a fecal discharge channel, prolong the residence time of the hollow rectal plug containing the drug in the rectum, prevent the drug from being diluted by the feces and discharge along with the feces, and continuously release the drug. The length and the inner diameter of the hollow rectal suppository containing the medicine can be individually designed according to the rectum size and the treatment requirement of a patient. The curve shape of the curve-shaped suppository shell can enable the hollow rectal suppository containing the medicine to be clung to the intestinal wall, long-time retention is realized, and the structure with narrow upper part and wide lower part is beneficial to the incorporation of the rectal suppository. The inner part spring provides supporting function, so that the hollow rectal suppository containing the medicine keeps complete form, resists certain pressure, and the outer part suppository shell is tightly attached to the intestinal wall after being taken into the rectum.
Disclosed is lentinus edodes fermented crude protein with anti-tumor activity as well as an extracting method and a preparation thereof. The protein is obtained through fermentation, salting-out, dialysis and drying of mycelia of lentinus edodes C91-3; the protein is light brown or earthy yellow powder which can be dissolved in water and has specific fragrance, the pH value of aqueous solution is 5.0 to 8.0, the molecular weight is 1 KD to 90 KD, and the protein contains 18 types of amino acids and various proteins. The experiment proves that in the anti-tumor experiment in vitro, the protein has obvious restraining and killing effects on H22, U14 and S180, and the functional intensity of the protein depends on the concentration of the protein and the time. The experiment proves that the strain fermented crude protein has strong effect of directly killing tumor cells. In the anti-tumor experiment in vivo, lentinus edodes C91-3 fermented crude protein has the effect of treating tumor. By adopting the lentinus edodes C91-3 fermented crude protein, the life time of H22 and U14 tumor-bearing mouse can be obviously lengthened, and the lentinus edodes C91-3 fermented crude protein has obvious restraining effect on H22 solid tumor. The lentinus edodes fermented crude protein has no toxic side effect through animal acute toxicity experiments and long-term toxicity experiments, thereby being safe and reliable.
BACKGROUND AND AIMS: Intestinal fibrosis is a common complication of Inflammatory Bowel Disease (IBD), namely Crohn's disease (CD) and ulcerative colitis (UC), but the precise mechanism by which it occurs is incompletely understood hampering the development of effective therapeutic strategies. Here, we aimed at inducing and characterizing an inflammation-mediated fibrosis in patient-derived organoids (PDOs) issued from crypts isolated from colonic mucosal biopsies of IBD pediatric patients and age matched-control subjects (CTRLs).
METHODS: Inflammatory-driven fibrosis was induced by exposing CTRL-, CD- and UC-PDOs to the pro-inflammatory cytokine TNF-α for one day, followed by a co-treatment with TNF-α and TGF-β1 for three days. Fibrotic response was proven by analyzing inflammatory and fibrotic markers by RT-qPCR and immunofluorescence. Transcriptomic changes were assessed by RNA-sequencing.
RESULTS: Co-treatment with TNF-α and TGF-β1 caused in CTRL- and IBD-PDOs morphological changes towards a mesenchymal-like phenotype and up-regulation of inflammatory, mesenchymal, and fibrotic markers. Transcriptomic profiling highlighted that in all intestinal PDOs, regardless of the disease, the co-exposure to TNF-α and TGF-β1 regulated EMT genes and specifically increased genes involved in positive regulation of cell migration. Finally, we demonstrated that CD-PDOs display a specific response to fibrosis compared to both CTRL- and UC-PDOs, mainly characterized by upregulation of nuclear factors controlling transcription.
CONCLUSIONS: This study demonstrates that intestinal PDOs may develop an inflammatory-derived fibrosis thus representing a promising tool to study fibrogenesis in IBD. Fibrotic PDOs show increased expression of EMT genes. In particular, fibrotic CD-PDOs display a specific gene expression signature compared to UC and CTRL-PDOs.
Participants will be randomized to either star to receive a capsule/day with omega-3 fatty acid from 1g Nannochloropsis sp. microalga (250 mg of EPA) for 6 weeks. Followed by a wash-out period of 10 weeks.
Clinical and epidemiological research shows that people with diabetes mellitus frequently experience diabetic cognitive impairment. Schisandrin A (SchA), one of the lignans found in the dried fruit of Schisandra chinensis, has a variety of pharmacological effects on immune system control, apoptosis suppression, anti-oxidation and anti-inflammation. The goal of the current investigation was to clarify the probable neuro-protective effects of SchA against streptozotocin-induced diabetes deficiencies of the spatial learning and memory in rats. The outcomes show that SchA therapy effectively improved impaired glucose tolerance, fasting blood glucose level and serum insulin level in diabetic rats. Additionally, in the Morris water maze test, diabetic rats showed deficits in spatial learning and memory that were ameliorated by SchA treatment. Moreover, giving diabetic rats SchA reduced damage to the hippocampus structure and increased the production of synaptic proteins. Further research revealed that SchA therapy reduced diabetic-induced hippocampus neuron damage and the generation of Aβ, as demonstrated by the upregulated phosphorylation levels of insulin signaling pathway connected proteins and by the decreased expression levels of inflammatory-related factors. Collectively, these results suggested that SchA could improve diabetes-related impairments in spatial learning and memory, presumably by reducing inflammatory responses and regulating the insulin signaling system.
The invention discloses a traditional Chinese medicine composition for treating or improving cognitive dysfunction and a preparation method thereof. The traditional Chinese medicine composition is prepared from the following raw materials: rhubarb, peach kernel, cowherb seed, common burreed rhizome and dried ginger. The invention further discloses a method for preparing the traditional Chinese medicine composition. The traditional Chinese medicine composition disclosed by the invention has the effects of clearing away heat and promoting diuresis, nourishing brain and improving the effect of the marrow sea god, can effectively improve the symptom of dementia and forgetfulness, and achieves the treatment effects of activating blood and dredging collaterals, resisting inflammation and removing blood stasis and protecting neurons. Animal behavioural experiments show that the traditional Chinese medicine composition has remarkable improving effect on cognitive dysfunction and anxiety emotion of mice. The immunofluorescence staining result shows that the traditional Chinese medicine composition of the invention protects axons, myelin sheaths and synapses and reduces neuronal cell apoptosis by inhibiting astrocyte and microglial cell proliferation. The toxicity experiment result shows that the traditional Chinese medicine composition is safe and has no toxic or side effect.
The invention is directed to A-lineage conotoxin peptides, which are conotoxin peptides that have strong homology in the signal sequence and the 3'-untranslated region of the genes coding for these peptides to the sequences in the  alpha -conotoxin peptides. The A-lineage conotoxin peptides include the  alpha -conotoxin peptides, the  alpha -conotoxin-like peptides and the  kappa -conotoxin peptides, described further below. The  alpha -conotoxin-peptides generally share a "core" sequence motif. This core sequence is termed the  alpha 3/5 core and is represented as Cys-Cys-Xaa-Xaa-Xaa-Cys-Xaa-Xaa-Xaa-Xaa-Xaa-Cys (SEQ ID NO:1). The  alpha -conotoxin-like peptides generally share a core sequence termed the  alpha 4/7 core and is represented as Cys-Cys-Xaa-Xaa-Xaa-Xaa-Cys-Xaa-Xaa-Xaa-Xaa-Xaa-Xaa-Xaa-Cys (SEQ ID NO:2). The  kappa -conotoxin peptides generally have a core sequence termed the  kappa 7/2/1/3 core and is represented as Cys-Cys-Xaa-Xaa-Xaa-Xaa-Xaa-Xaa-Xaa-Cys-Xaa-Xaa-Cys-Xaa-Cys-Xaa-Xaa-Xaa-Cys (SEQ ID NO:3).
The main causative factors of diabetic nephropathy (DN), a common complication of diabetes mellitus, are metabolic abnormalities and hemodynamic changes. However, studies have shown that the immune-inflammatory response also plays an important role in DN pathogenesis. Therefore, in this study, we analyzed the causal relationship and immune infiltration between inflammatory factors and DN using Mendelian randomization (MR) and bioinformatics techniques. We analyzed the causal relationship between 91 inflammatory factors and DN using two-sample MR dominated by the results of inverse variance-weighted analysis. Based on the MR analysis, the immune mechanism of inflammatory factors in DN was further explored using immune cell infiltration analysis. MR analysis indicated a positive causal relationship between DN and IL1A, caspase 8 (CASP8), macrophage colony-stimulating factor 1, IL10, STAM-binding protein, and tumor necrosis factor ligand superfamily member 12 (TNFSF12) and a negative causal relationship between DN and cystatin D, fibroblast growth factor 19, neurturin, and TNFSF14. The pathogenic mechanism of CASP8 may involve the recruitment of CD4+ T cells and macrophages for DN infiltration. In this study, we found a causal relationship between DN and IL1A, CASP8, macrophage colony-stimulating factor 1, IL10, STAM-binding protein, TNFSF12, cystatin D, fibroblast growth factor 19, neurturin, and TNFSF14. Bioinformatic immune infiltration analysis further revealed that CASP8 regulates DN by influencing the infiltration of immune cells, such as T cells and macrophages.
The exposure is intra-operative hypotension during the ERCP procedure (hypotension is defined as a 20% reduction in the mean arterial blood pressure (MAP) or systolic arterial blood pressure (SAP) \< 90 mmHg during CBD manipulation or after obstruction relief). The basal blood pressure (BP) will be the immediate reading before the endoscope insertion while the patient is in his left lateral position.
OBJECTIVE: Most studies investigated the relationship between COVID-19 and Guillain-Barré syndrome (GBS) by comparing the incidence of GBS before and during the pandemic of COVID-19. However, the findings were inconsistent, probably owing to varying degrees of the lockdown policy. The quarantine requirements and travel restrictions in China were lifted around December 7, 2022. This study aimed to explore whether the relative frequency of GBS increased during the major outbreak in the absence of COVID-19-mandated social restrictions in China.
METHODS: GBS patients admitted to the First Hospital, Shanxi Medical University, from December 7, 2022 to February 20, 2023, and from June, 2017 to August, 2019 were included. The relative frequencies of GBS in hospitalized patients during different periods were compared. The patients with and without SARS-CoV-2 infection within six weeks prior to GBS onset formed the COVID-GBS group and non-COVID-GBS group, respectively.
RESULTS: The relative frequency of GBS among hospitalized patients during the major outbreak of COVID-19 (13/14,408) was significantly higher than that before the COVID-19 epidemic (29/160,669, P < 0.001). More COVID-GBS patients (11/13) presented AIDP subtype than non-COVID-GBS cases (10/27, P = 0.003). The mean interval between onset of infective symptoms and GBS was longer in COVID-GBS (21.54 ± 11.56 days) than in non-COVID-GBS (5.76 ± 3.18 days, P < 0.001).
CONCLUSIONS: COVID-19 significantly increased the incidence of GBS. Most COVID-GBS patients fell into the category of AIDP, responded well to IVIg, and had a favorable prognosis.
PURPOSE:To obtain a chemically stable anticarious agent, containing glabridin as an active ingredient, having remarkable anticarious action in a small amount thereof with any taste, odor and side effects and capable of being freely blended in cosmetics, quasidrugs, foods, etc. CONSTITUTION:An anticarious agent obtained by extracting the root part of Glycyrrhiza glabra var. glandulifera or an aqueous extraction residue thereof with an organic solvent having intermediate polarity, purifying the resultant extract and containing the obtained glabridin expressed by formula I and/or glabrene expressed by formula II as an active ingredient. In use, the aforementioned agent is employed in the form of a solution, solid agent, etc., or may be used by blending in a dentifrice, mouthwash, etc. For example, the adequate amount thereof blended in the dentifrice is about 1-100ppm expressed in terms of the above-mentioned active ingredient. The glabridin and grabrene which are the active ingredient is obtained by extracting the root part or the aqueous extraction residue with the organic solvent having intermediate polarity and purifying the prepared extract.
BACKGROUND: Hemorrhage accounts for the most preventable deaths after trauma. Resuscitation is guided by studies that demonstrate improved outcomes in patients receiving whole blood or balanced administration of blood products. Platelets present a logistical challenge due to short shelf life and need for refrigeration. Platelet-derived extracellular vesicles (PEVs) are a possible platelet alternative. Platelet-derived extracellular vesicles are secreted from platelets, have hemostatic effects and mitigate inflammation and vascular injury, similar to platelets. This pilot study aimed to elucidate the therapeutic effects of PEVs in a rat model of uncontrolled hemorrhage.
METHODS: Male rats were anesthetized and femoral vessels cannulated. Vital signs (MAP, HR, and RR) were monitored. Electrolytes, lactate and ABG were obtained at baseline, 1-hour and 3-hours post injury. Laparotomy was performed, 50% of the middle hepatic lobe excised and the abdomen packed with gauze. Rats received 2 mL PEVs or lactated Ringers (LR) over 6 minutes immediately after injury. Peritoneal blood loss was quantified using preweighed gauze at 5 minutes, 15 minutes, 30 minutes, 45 minutes, and 60 minutes. Laparotomy was closed 1-hour postinjury. Animals were monitored for 3 hours postinjury then euthanized. Generalized Linear Mixed Effects models were performed to assess effects of treatment and time on lactate and MAP.
RESULTS: Twenty-one rats were included (11 LR, 10 PEV). Overall blood loss was between 6 mL and 10 mL and not significantly different between groups. There was a 36% mortality rate in the LR group and 0% mortality in the PEV group ( p = 0.03). The LR group had significantly higher lactates at 1 hour ( p = 0.025). At 15 minutes, 45 minutes, 60 minutes, and 180 minutes, the MAP of the PEV group was significantly higher than the LR group.
CONCLUSION: Early studies are encouraging regarding the potential use of PEVs in uncontrolled hemorrhagic shock based on improved survival and hemodynamics.
Plasma concentrations of tretinoin and its major metabolites (isotretinoin and 4-oxo-isotretinoin) were evaluated in 20 subjects in an open-label, randomized, pharmacokinetic study. Subjects aged 10 years to less than 17 years old with acne vulgaris applied approximately 3.5 g of ALTRENO to the skin of the entire face (excluding eyes and lips), neck, upper chest, upper back and shoulders once daily for 14 days. Single-dose pharmacokinetic (PK) characteristics were determined from samples drawn on Days 1 and 2 of dosing and steady-state PK characteristics were determined from samples drawn on Days 14 and 15 under maximal use conditions. The mean baseline corrected Cmax and AUC0-t of tretinoin and its metabolites after once daily application of ALTRENO for 14 days are shown below:

The mean concentrations of tretinoin and its metabolites (isotretinoin and 4‑oxo‑isotretinoin) remain relatively stable and unchanged over the 24‑hour period after both the Day 1 dose and the Day 14 dose. Systemic concentrations of tretinoin appear to be at or near steady state by Day 14. Mean accumulation ratios of the baseline corrected AUC between Day 14 and Day 1 were 1.5, 4.5 and 7.3 for tretinoin, isotretinoin, and 4-oxo-isotretinoin, respectively.
Patients with short bowel syndrome (SBS) have a risk for cholelithiasis and cholecystitis, particularly those who have received long-term parenteral nutrition (PN). Teduglutide (Revestive), a glucagon-like peptide-2 (GLP-2) analogue, is the first effective therapy approved for treating patients with SBS via self-subcutaneous injection. It also pharmacologically inhibits gallbladder contraction, which may increase the risks for cholelithiasis and cholecystitis. Here, we report a case of cholecystitis occurring after the introduction of a GLP-2 analogue in a patient with SBS and cholelithiasis. A 16-year-old girl, with a residual intestinal anatomy of 5 cm jejunum and left colon, was referred to our hospital for further treatment of SBS. She underwent jejunocolic anastomosis 2 months later. After that, she received PN for 2.5 years. Teduglutide treatment was initiated to reduce PN dependence. Several asymptomatic gallbladder stones were found during a routine ultrasound examination before drug initiation. On day 31 of teduglutide treatment, right subcostal pain with fever occurred, and the patient was diagnosed with acute cholecystitis. GLP-2 analogue treatment was temporarily discontinued. The patient underwent gallbladder drainage followed by cholecystectomy 3 weeks later. Histopathological findings illustrated mucosal hyperplasia of the gallbladder. Her postoperative course was uneventful, and teduglutide was restarted 2 weeks postoperatively. GLP-2 analogues promote gallbladder refilling and epithelial hyperplasia, which may be a risk factor for cholecystitis in patients with cholelithiasis, as observed in our patient. Based on our experience, patients with SBS and established asymptomatic cholelithiasis may be considered for prophylactic cholecystectomy before the administration of GLP-2 analogues.
<P>PROBLEM TO BE SOLVED: To provide a composition having an excellent neovascularization inhibitory action from an inexpensive and relatively easily available material not having a problem on safety, preferably barley, by a simple treatment method suitable for practical production in a factory scale without passing through a troublesome purification process.  <P>SOLUTION: This composition for inhibiting neovascularization contains an ingredient originated from a gramineae plant, preferably an ingredient originated from barley, as active ingredient having a neovascularization inhibitory action. The ingredient originated from barley is selected from the group consisting of an unmilled barley ethyl alcohol extraction fraction and an unmilled barley alkali extraction fraction. The composition for inhibiting the neovascularization is a composition for treating or preventing diseases having neovascularization to be inhibited, concretely diseases caused by abnormal neovascularization in tumors or cancers, chronic inflammations or retinopathy. The composition is in a form selected from the group consisting of food additives, food materials, foods, drinks, medicines/quasi-drugs, and feeds for inhibiting neovascularization.  <P>COPYRIGHT: (C)2007,JPO&INPIT